ArticleBMC biotechnology2025

Design, synthesis, and biological evaluation of Osimertinib-Cy7 (OSA-Cy7) conjugate as potential theranostic agent targeting activating EGFR mutations.

Ying Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.